Precision BioSciences, Inc. (NASDAQ:DTIL) Short Interest Up 11.8% in November

Precision BioSciences, Inc. (NASDAQ:DTIL) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 239,900 shares, an increase of 11.8% from the October 31st total of 214,600 shares. Based on an average trading volume of 75,900 shares, the days-to-cover ratio is currently 3.2 days. Approximately 6.5% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Precision BioSciences in a research report on Thursday, August 22nd.

Precision BioSciences Trading Down 9.6 %

NASDAQ DTIL opened at $6.21 on Wednesday. The company has a market cap of $47.63 million, a PE ratio of 103.52 and a beta of 1.41. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. Precision BioSciences has a 12 month low of $6.18 and a 12 month high of $19.43. The stock has a 50 day moving average of $8.29 and a 200-day moving average of $9.60.

Institutional Investors Weigh In On Precision BioSciences

An institutional investor recently raised its position in Precision BioSciences stock. Geode Capital Management LLC boosted its holdings in Precision BioSciences, Inc. (NASDAQ:DTIL) by 40.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 65,974 shares of the company’s stock after acquiring an additional 19,088 shares during the period. Geode Capital Management LLC owned 0.86% of Precision BioSciences worth $591,000 as of its most recent filing with the Securities and Exchange Commission. 37.99% of the stock is owned by institutional investors.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.